^
BIOMARKER:
HER-2 negative
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A2 - Guideline
BMC Cancer - 1 week (NewA2)
|
ribociclib Sensitive: A2 - Guideline
BMC Cancer - 1 week - (New C3)
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A2 - Guideline
BMC Cancer - 1 week (NewA2)
|
palbociclib Sensitive: A2 - Guideline
BMC Cancer - 1 week - (New C3)
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
cisplatin + capecitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
ixabepilone Sensitive: A2 - Guideline
|
ixabepilone Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
tamoxifen Sensitive: A2 - Guideline
|
tamoxifen Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
fulvestrant + anastrozole Sensitive: A2 - Guideline
|
fulvestrant + anastrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
fulvestrant + letrozole Sensitive: A2 - Guideline
|
fulvestrant + letrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A2 - Guideline
|
abemaciclib Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
exemestane Sensitive: A2 - Guideline
|
exemestane Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
EC Sensitive: A2 - Guideline
|
EC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CMF Sensitive: A2 - Guideline
|
CMF Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
AC Sensitive: A2 - Guideline
|
AC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
TAC Sensitive: A2 - Guideline
|
TAC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
GT Sensitive: A2 - Guideline
|
GT Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
epirubicin Sensitive: A2 - Guideline
|
epirubicin Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
|
lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
HER-2 negative
|
Esophageal Cancer
|
HER-2 negative
|
Esophageal Cancer
|
XP Sensitive: A2 - Guideline
|
XP Sensitive: A2 - Guideline
|
HER-2 negative
|
Esophageal Cancer
|
HER-2 negative
|
Esophageal Cancer
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
HER-2 negative
|
Esophageal Cancer
|
HER-2 negative
|
Esophageal Cancer
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
capecitabine + oxaliplatin Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
POL 6326 Sensitive: B - Late Trials
|
POL 6326 Sensitive: B - Late Trials
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: B - Late Trials
|
ramucirumab Sensitive: B - Late Trials
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
ramucirumab Sensitive: B - Late Trials
|
ramucirumab Sensitive: B - Late Trials
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
HER-2 negative
|
Breast Cancer
|
HER-2 negative
|
Breast Cancer
|
abemaciclib Sensitive: B - Late Trials
|
abemaciclib Sensitive: B - Late Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: C2 – Inclusion Criteria
|
olaparib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
E7389-LF Sensitive: C2 – Inclusion Criteria
|
E7389-LF Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
bevacizumab + ME-344 Sensitive: C2 – Inclusion Criteria
|
bevacizumab + ME-344 Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria
|
capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
cabazitaxel Sensitive: C2 – Inclusion Criteria
|
cabazitaxel Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
anlotinib Sensitive: C2 – Inclusion Criteria
|
anlotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
camrelizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
|
camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria
|
camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
Gastric Cancer
|
HER-2 negative
|
Gastric Cancer
|
camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria
|
camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
MLN8237 Sensitive: C2 – Inclusion Criteria
|
MLN8237 Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
trastuzumab + bevacizumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + bevacizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
capecitabine + bendamustine Sensitive: C2 – Inclusion Criteria
|
capecitabine + bendamustine Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
LY2780301 Sensitive: C2 – Inclusion Criteria
|
LY2780301 Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
paclitaxel oral Sensitive: C2 – Inclusion Criteria
|
paclitaxel oral Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
GC Sensitive: C3 – Early Trials
|
GC Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
NLG8189 Resistant: C3 – Early Trials
|
NLG8189 Resistant: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
APG-1387 Sensitive: C3 – Early Trials
|
APG-1387 Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials
|
gimeracil / oteracil / tegafur Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
nedaplatin Sensitive: C3 – Early Trials
|
nedaplatin Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
capecitabine + D19466 Sensitive: C3 – Early Trials
|
capecitabine + D19466 Sensitive: C3 – Early Trials
|
HER-2 negative
|
NSCLC
|
HER-2 negative
|
NSCLC
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
TEC Sensitive: C3 – Early Trials
|
TEC Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
FEC Sensitive: C3 – Early Trials
|
FEC Sensitive: C3 – Early Trials
|
HER-2 negative
|
Gastric Adenocarcinoma
|
HER-2 negative
|
Gastric Adenocarcinoma
|
cisplatin + paclitaxel + capecitabine Sensitive: C3 – Early Trials
|
cisplatin + paclitaxel + capecitabine Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
cyclophosphamide + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials
|
cyclophosphamide + non-pegylated liposomal doxorubicin Sensitive: C3 – Early Trials
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
docetaxel + doxorubicin hydrochloride Resistant: C4 – Case Studies
|
docetaxel + doxorubicin hydrochloride Resistant: C4 – Case Studies
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor + CDK6 inhibitor Sensitive: C4 – Case Studies
|
CDK4 inhibitor + CDK6 inhibitor Sensitive: C4 – Case Studies
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
trastuzumab Resistant: D – Preclinical
|
trastuzumab Resistant: D – Preclinical
|
HER-2 negative
|
Estrogen Receptor Positive Breast Cancer
|
HER-2 negative
|
Estrogen Receptor Positive Breast Cancer
|
ZEN-3694 Sensitive: D – Preclinical
|
ZEN-3694 Sensitive: D – Preclinical
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
etoposide IV Sensitive: D – Preclinical
|
etoposide IV Sensitive: D – Preclinical
|
